Dif®cult asthma' is a term widely used when asthmatic symptoms are uncontrolled by conventional pharmacological and environmental approaches. A treatment-centred de®nition of this sort is favoured by the European Respiratory Society (Box 1) 1 . However,`dif®cult' is just one of many descriptors used by physicians, nurses and patients for the severe end of the asthma spectrum, others being chronic persistent, life-threatening, near fatal, near miss, unstable, brittle and severe. These terms are used in different ways by different people; for instance,`severe' might refer either to a patient with occasional lifethreatening attacks or to a patient whose day-to-day life is gravely impaired by chronic persistent symptoms. Such ambiguityÐtroublesome in both clinical and research settingsÐcould be addressed by a structured use of phenotypic descriptions.
CLINICAL PHENOTYPES
The value of speci®c phenotypes has long been recognized in medicineÐthe myxoedematous facies, the acromegalic jaw. In asthma the phenotypic approach has so far employed clinical/physiological patterns such as combinations of symptoms, treatment response, lung function or bronchial reactivity. Originally these phenotypes were devised largely for epidemiological studies and the de®nitions had to be applicable in the ®eld. With the advent of new markers of airway in¯ammation such as exhaled nitric oxide 2 or in¯ammatory indices in induced sputum 3 , there was an opportunity to make the phenotypes more speci®c. Their use at the severe end of the spectrum could prove particularly bene®cial in a group of patients who are at present dif®cult to study and represent a heavy burden on health service resources.
With the increased recognition of genetic polymorphisms relevant to asthma, the clinical phenotypes could then be linked to genotypes, with the prospect of better understanding of pathogenesis and new approaches to treatment. What we need are phenotypes that are both re®ned and robustÐa challenge for clinical researchers 4 .
SEVERE ASTHMA PHENOTYPES
So, what are the attributes of a phenotype that will be useful clinically and in research? First, the phenotype must be appropriate for the circumstances. A de®nition that included the degree of eosinophilic in®ltration of the bronchial mucosa would clearly be unsuitable for an epidemiological study. Second, the criteria must be precise. Bronchial responsiveness to a non-speci®c stimulus such as methacholine is readily quanti®able, global assessment of symptoms is not; if symptoms are to be included in a phenotype, some method of quanti®cation must be applied. Third, the phenotype must be easily recognized in the context of the question being addressed, even if there will be delay in completing the picture; a blood sample is readily taken, but the eosinophil count may not be available on the day. Fourth, the phenotype must have a clear end in sightÐ in relation to mechanism, aetiology or therapy.
Brittle asthma
Brittle asthma is an example of a severe asthma phenotype which, when de®ned robustly, led to the identi®cation of speci®c risk factors (atopy, psychosocial) and treatment responses (subcutaneous terbutaline infusions). Brittle asthma was originally described in terms of chaotic swings in peak¯ow and symptoms 5 without speci®cation of the Asthma which is poorly controlled in terms of chronic symptoms, episodic exacerbations, persistent and variable air¯ow obstruction and a continued requirement for short acting b 2 -agonists despite delivery of a reasonable dose of inhaled corticosteroids.
The ERS Taskforce added the following riders to the de®nition:
. A reasonable dose of inhaled corticosteroids constitutes, for adults, 42000 mg/day of beclomethasone, 1600 mg/day of budesonide and 1000 mg/day of¯uticasone and for children 800 mg/day of either beclomethasone or budesonide or 400 mg/day of¯uticasone . Patients may require courses of oral corticosteroids or a regular dose of oral corticosteroid to maintain reasonable control of the disease . Rarely, control of the disease may be totally unin¯uenced by corticosteroid therapy.
Box 1 European Respiratory Society de®nition of dif®cult/therapyresistant asthma
degree of variation or the amount of treatment taken. The ®rst British Asthma Guidelines from 1990 described brittle asthma in a different wayÐbroadly, as patients who have sudden precipitous attacks out of the blue 6 . Here were two different phenotypes with the same name, the common feature being the tendency to experience repeated severe attacks. We felt that the word`brittle' was appropriate for the ability to develop repeated severe attacks and therefore proposed two separate subtypes, types I and II 7 . Type I patients show a greater than 40% variation in peak¯ow (amplitude % maximum) for more than 50% of the time, for a period of at least 150 days despite maximal medical treatment (i.e. at least 1500mg of inhaled beclomethasone or equivalent). Type II patients have repeated severe attacks on a background of apparently good asthma control.
The type II phenotype is generally accepted as rare and seldom life-threatening. Characteristically, attacks are rapid in onset but quick to subside. Such attacks were seen during the outbreaks of severe acute asthma in Barcelona where patients were often ventilated for only two or three hours and were ®t for discharge a few hours later 8 . The rapidity of onset and recovery is consistent with an IgE-mediated immediate response, as proved to be the case in Barcelona where the cause was found to be soya bean dust made airborne during off-loading at the docks.
The type I phenotype is more open to debate. The original quantitative components were admittedly empirical, but did stand up to research enquiry. A series of case± control studies asking straightforward questions con®rmed differences between this phenotype and that of patients with severe asthma who lacked that degree of peak¯ow variation but were taking equivalent doses of inhaled corticosteroids. The phenotype was found to be associated with strong atopic characteristics 9 , psychosocial morbidity 10 and an increased frequency of adverse reactions to foods 11 . In addition, female patients with this phenotype are at considerable excess risk of premenstrual asthma, which is often severe.
These studies raised two particular questions about the type I phenotype. First, do these associations merely re¯ect greatly enhanced bronchial responsiveness? This question is complex and the identi®ed contributory factors are interrelated. While type I individuals are highly atopic they are also more likely to be continually exposed to high levels of allergen exposure, particularly to pets, at home 12 thus perpetuating an allergen-driven bronchial hyperresponsiveness. Application of this phenotype has thus identi®ed a causal pathway that in theory might be interrupted. But patients tend to resist the idea of getting rid of their pets. One reason for the high pet ownership in this group is that many have suffered severe domestic troubles and ®nd pets altogether more reliable than people.
The position with food allergy/intolerance, very common in this group 11 , is the same. Whereas removal of foods from the diet, identi®ed as causes of adverse reactions, can sometimes yield remarkable long-term bene®ts, in other cases the bene®t is merely a reduction in the number or severity of attacks with continuing airway lability. So this phenotype may include not only patients in whom dietary exposure may have helped initiate the airway in¯ammation but also patients in whom the dietary factor triggers an underlying airway hyperresponsiveness.
Secondly, are these patients`simply' examples of severe asthma or are there other factors which contribute to their symptoms? The possible association of other diagnoses, such as chronic obstructive pulmonary disease or bronchiectasis, in patients with asthma is well recognized. However, in severe asthma, particularly type I brittle asthma which largely affects women, there is a widely held belief that many of the symptoms are due not to asthma but to vocal cord dysfunction 13 , long recognized to be associated with psychological factors. Vocal cord adduction can cause rapid reductions in air¯ow (and hence rapid onset of attacks of wheezy breathlessness) and could equally produce wide swings in peak¯ow, the main characteristic of the type I phenotype. This phenotype could thus be interrogated (with this question in view) by considering the rapidity of onset of attacks rather than the underlying degree of air¯ow variability per se.
So, might laryngeal hyperresponsiveness be a major contributor to those rapid-onset attacks, mediated through vocal cord adduction? Some patients with bronchial hyperresponsiveness of extreme degree ®nd that a forced expiration in itself will cause further airway narrowing and symptoms. It is plausible, therefore, that the same may hold if the larynx is hyperresponsive. But if this is the physiology, what is the pathology? Why is the larynx irritable in the ®rst instance? This may, for instance, be a re¯ection of allergic in¯ammation in the larynx. If we call the clinical picture associated with nasal mucosal irritabilitỳ rhinitis' and that with lower airway irritability`asthma', so the larynx could be irritable and cause symptoms through an in¯ammatory process in exactly the same way. There is some laboratory evidence for this notion, in that the laryngeal submucosa contains substantial numbers of antigen presenting cells 14 Ðalthough, as far as I am aware, there have been no speci®c studies of the histopathological appearances of the larynx in asthma. On the other hand, the rapid-onset attacks seen in this phenotype may genuinely be due to asthma itself, and the two mechanisms could coexist. But whether the site of airway narrowing is at lower airway or laryngeal level the likely mechanism will be neural. Questioning the phenotype has thus opened a channel of research for which there is support from a different angle.
J O U R N A L O F T H E R O Y A L S O C I E T Y O F M E D I C I N E
Another label often applied to type I brittle asthma patients, and indeed to other patients with attacks of wheezy breathlessness presenting in accident and emergency departments, is`hyperventilator'. Patients who have very rapid onset attacks may by the time that they reach hospital be in a rapid recovery phase and all the examining doctor ®nds are a modest tachycardia (often attributed to b-agonist treatment) and tachypnoea. Arterial blood gases may reveal normal oxygen and low carbon dioxide tensions. Hyperventilation is the diagnosis usually made but these ®ndings are fully compatible with the recovery phase after a rapid-onset rapid-recovery attack of asthma (Box 2). Hyperventilation in a patient who has airway hyperresponsiveness can cause airway narrowing in its own right, whether at laryngeal or lower airway level, thus again bringing laryngeal abnormalities into the picture.
These pathophysiological pathways are, to an extent, speculative but the arguments have been arrived at by questioning the phenotype.
USING THE PHENOTYPES
As more is understood about the different patterns of asthma, these phenotypes will doubtless need to be modi®ed. But any such changes must be soundly based and not made frequently since this would be self-defeating. When using phenotypes to predict risk, we must remember that a patient may not remain embedded in a speci®c phenotype all his or her life. The pattern of asthma may move from less to more severe or the reverse; these longitudinal changes over time re¯ect the natural history of asthma. A more speci®c approach to phenotype de®nition incorporating, for instance, in¯am-matory markers 2, 3 , may well help in understanding this natural history. For example, patients with severe asthma who have enhanced numbers of eosinophils on bronchial biopsy are likely to have a greater basement membrane thickening and greater numbers of transforming growth factor b positive cells in the airways 15 . These patients are likely to change their phenotype over time with remodelling of the airways. Anecdotally, we ®nd that type I brittle asthma patients become less brittle as they get older; airway remodelling, and the resultant more persistent air¯ow obstruction, may be a contributory factor.
LINKING PHENOTYPE TO GENOTYPE
The ultimate bene®t from the approach I have outlined is to link the phenotype into the genotype. A substantial number of genetic polymorphisms have now been associated with asthma or atopy and some of these genotypes appear linked to clinical severity. The b-adrenergic receptor on chromosome 5, for instance, expresses several different haplotypes of which the Arg 16 ?Gly 16 allele is more associated with nocturnal asthma while the Gln 27 ?Glu 27 allele may be more associated with less reactive airways 16 . In general, the phenotypes used in these studies to date have not been as speci®c as is now possible with in¯ammatory markers and more precise clinical criteria.
The use of a phenotype approach will help unpick the multiple interactions of genes and environment in severe asthma. Development of a hierarchical phenotypic approach, testable in practice, will provide information that could be missed with the existing unstructured approach. How best this can be devised should become a matter for debate. 
J O U R N A L O F T H E R O Y A L S O C I E T Y O F M E D I C I N E
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